|
03 Feb 2020 |
Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
|
|
03 Feb 2020 |
Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis
|
|
03 Feb 2020 |
Mesoblast submits completed biologics license application for Ryoncil to US FDA
|
|
02 Feb 2020 |
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
|
|
02 Feb 2020 |
Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription
|
|
02 Feb 2020 |
Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer
|
|
02 Feb 2020 |
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum
|
|
02 Feb 2020 |
AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
|
|
02 Feb 2020 |
AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
|
|
02 Feb 2020 |
CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet as treatments for hypercholesterolaemia
|
|
02 Feb 2020 |
EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
|
|
31 Jan 2020 |
Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Trial
|
|
31 Jan 2020 |
Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)
|
|
30 Jan 2020 |
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
|
|
30 Jan 2020 |
Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder
|
|
30 Jan 2020 |
FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb
|
|
30 Jan 2020 |
Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
|
|
30 Jan 2020 |
Bayer application for nifurtimox to treat pediatric patients with Chagas disease submitted for approval in US
|
|
30 Jan 2020 |
Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV
|
|
30 Jan 2020 |
vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
|
|
30 Jan 2020 |
Janssen Announces European Commission Approval for Expanded Use of Erleada®▼ (apalutamide) for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
|
|
30 Jan 2020 |
Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer
|
|
30 Jan 2020 |
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
|
|
28 Jan 2020 |
Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
|
|
28 Jan 2020 |
Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors
|
